ERBB2 and non-small cell lung carcinoma: For precision medicine, neural networks trained on multiomic datasets (e.g., methylation profiles, proteomics) could identify patient-specific vulnerabilities—such as HER2/neu amplification in breast cancer metastases or ALK fusions in NSCLC—and enable tailored immunotherapy or small-molecule regimens [163,166].